Home » Stocks » HTG Molecular Diagnostics

HTG Molecular Diagnostics, Inc. (HTGM)

Stock Price: $0.543 USD -0.107 (-16.45%)
Updated Aug 12, 2020 4:00 PM EDT - Market closed
After-hours: $0.565 +0.022 (4.03%) Aug 12, 7:58 PM

Stock Price Chart

Key Info

Market Cap 38.39M
Revenue (ttm) 14.39M
Net Income (ttm) -20.30M
Shares Out 67.09M
EPS (ttm) -0.30
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 12, 2020
Last Price $0.543
Previous Close $0.650
Change ($) -0.107
Change (%) -16.45%
Day's Open 0.600
Day's Range 0.537 - 0.610
Day's Volume 4,977,382
52-Week Range 0.267 - 1.160

More Stats

Market Cap 38.39M
Enterprise Value 18.41M
Earnings Date (est) Nov 11, 2020
Ex-Dividend Date n/a
Shares Outstanding 67.09M
Float 48.68M
EPS (basic) -0.33
EPS (diluted) -0.30
FCF / Share -0.27
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 1.06M
Short Ratio 0.10
Short % of Float 0.75%
Beta 1.72
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 2.67
PB Ratio 2.00
Revenue 14.39M
Operating Income -19.33M
Net Income -20.30M
Free Cash Flow -17.42M
Net Cash 19.98M
Net Cash / Share 0.28
Gross Margin -1.93%
Operating Margin -134.27%
Profit Margin -141.00%
FCF Margin -121.02%
ROA -32.46%
ROE -133.74%
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (4)

Buy 3
Overweight 0
Hold 1
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(139.37% upside)
Current: $0.543
Target: 1.30
*Average 12-month price target from 4 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth-10.7%45.69%187.56%27%21.41%48.41%-
Gross Profit10.2916.419.791.000.710.12-
Operating Income-18.96-16.16-17.72-24.33-18.89-12.85-11.92
Net Income-19.30-16.45-18.96-26.04-21.40-13.96-11.77
Shares Outstanding38.1027.5210.607.114.520.100.10
Earnings Per Share-0.51-0.60-1.79-3.66-5.03-175.03-147.48
Operating Cash Flow-16.70-13.17-16.57-22.23-19.24-13.00-11.82
Capital Expenditures-1.10-0.95-1.02-1.95-1.34-0.86-0.78
Free Cash Flow-17.80-14.12-17.59-24.18-20.58-13.85-12.60
Cash & Equivalents36.3031.119.9711.8131.503.611.82
Total Debt11.259.688.7511.7810.8010.52-
Net Cash / Debt25.0521.431.210.0320.70-6.911.82
Book Value23.9721.09-3.06-5.5916.89-69.67-58.25
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name HTG Molecular Diagnostics, Inc.
Country United States
Employees 108
CEO John L. Lubniewski

Stock Information

Ticker Symbol HTGM
Stock Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Unique Identifier NASDAQ: HTGM
IPO Date May 6, 2015


HTG Molecular Diagnostics, Inc. a commercial stage life sciences company, focuses on the precision medicine. The company offers instrumentation; consumables comprising assay kits; and software that automate sample processing and profiles various molecular targets. Its platforms generate a molecular profiling library for detection using next-generation sequencing. The company's marketed panels include HTG EdgeSeq oncology biomarker panel; HTG EdgeSeq immuno-oncology assay; HTG EdgeSeq DLBCL cell of origin assay; HTG EdgeSeq path assay; HTG EdgeSeq miRNA whole-transcriptome assay; HTG EdgeSeq DLBCL cell of origin assay EU; HTG EdgeSeq ALKPlus assay EU;HTG EdgeSeq precision immuno-oncology panel; HTG lung fusions assay; HTG autoimmune panel; and HTG mouse mRNA tumor response panel. It serves biopharmaceutical companies, academic research centers, and molecular testing laboratories. HTG Molecular Diagnostics, Inc. distributes its instruments and consumables directly in the United States and Europe; and through distributors in parts of Europe and internationally. The company has a governing agreement with QIAGEN Manchester Limited; and an agreement with Illumina, Inc. for the development of nuclease-protection-based RNA or DNA profiling tests. The company was formerly known as HTG, Inc. and changed its name to HTG Molecular Diagnostics, Inc. in March 2011. HTG Molecular Diagnostics, Inc. was incorporated in 1997 and is based in Tucson, Arizona.